[go: up one dir, main page]

CL2018000463A1 - Compuestos deuterados y usos de los mismos - Google Patents

Compuestos deuterados y usos de los mismos

Info

Publication number
CL2018000463A1
CL2018000463A1 CL2018000463A CL2018000463A CL2018000463A1 CL 2018000463 A1 CL2018000463 A1 CL 2018000463A1 CL 2018000463 A CL2018000463 A CL 2018000463A CL 2018000463 A CL2018000463 A CL 2018000463A CL 2018000463 A1 CL2018000463 A1 CL 2018000463A1
Authority
CL
Chile
Prior art keywords
deuterated compounds
hne
mda
pathogenesis
implicated
Prior art date
Application number
CL2018000463A
Other languages
English (en)
Inventor
Todd Brady
Scott Young
William A Kinney
Susan Macdonald
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Publication of CL2018000463A1 publication Critical patent/CL2018000463A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención proporciona el tratamiento, prevención y/o reducción del riesgo de una enfermedad, trastorno o condición en la que la toxicidad por aldehído está implicada en la patogénesis, incluidos trastornos oculares, trastornos de la piel, condiciones asociadas con efectos perjudiciales de los agentes ampollantes, y enfermedades autoinmunes, inflamatorias, neurológicas y cardiovasculares mediante el uso de una amina primaria para secuestrar aldehídos tóxicos, tales como MDA y HNE
CL2018000463A 2015-08-21 2018-02-21 Compuestos deuterados y usos de los mismos CL2018000463A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562208223P 2015-08-21 2015-08-21

Publications (1)

Publication Number Publication Date
CL2018000463A1 true CL2018000463A1 (es) 2018-08-17

Family

ID=58100876

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000463A CL2018000463A1 (es) 2015-08-21 2018-02-21 Compuestos deuterados y usos de los mismos

Country Status (15)

Country Link
US (5) US10550085B2 (es)
EP (2) EP4400106A1 (es)
JP (2) JP6947406B2 (es)
KR (1) KR102664994B1 (es)
CN (2) CN108135907A (es)
AU (1) AU2016311158A1 (es)
BR (1) BR112018003250A2 (es)
CA (1) CA2996183A1 (es)
CL (1) CL2018000463A1 (es)
CO (1) CO2018002822A2 (es)
ES (1) ES2989113T3 (es)
IL (1) IL257611A (es)
MX (1) MX2018002155A (es)
WO (1) WO2017035077A1 (es)
ZA (1) ZA201801678B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
WO2017147617A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CA3032521A1 (en) * 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
WO2018039197A1 (en) * 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
ES2968462T3 (es) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Sal polimórfica de 6-cloro-3-amino-2(2-hidroxiprolil) quinolina y usos de la misma
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
EP3890732A4 (en) * 2018-12-05 2022-08-24 Aldeyra Therapeutics, Inc. INJECTABLE FORMULATIONS
US11932617B2 (en) 2018-12-18 2024-03-19 Zhuhai United Laboratories Co., Ltd. Compound for use in retinal diseases
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113767090B (zh) * 2019-12-30 2024-05-28 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN115843293B (zh) * 2021-06-25 2025-01-24 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
KR20250111213A (ko) * 2022-11-26 2025-07-22 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 피리딘 페닐 화합물을 포함하는 안과용 제형, 이의 제조 방법, 및 이의 용도

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
JPS6192592A (ja) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
BR9106193A (pt) 1990-10-22 1993-03-23 Bausch & Lomb Metodo e composicao para limpar lentes de contato
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
JP2746832B2 (ja) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 眼局所抗アレルギー剤
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JPH08175985A (ja) 1994-12-26 1996-07-09 Lion Corp 点眼剤
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
CN1228084A (zh) 1996-08-01 1999-09-08 道农业科学公司 具有杀菌活性的4－取代的喹啉衍生物
ATE232863T1 (de) 1996-08-06 2003-03-15 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
ATE336485T1 (de) 1997-05-02 2006-09-15 Schering Ag Substituierte heterocyclen und deren verwendung in arzneimitteln
JPH10306022A (ja) 1997-05-06 1998-11-17 Lion Corp 点眼剤
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
JP3568108B2 (ja) 1999-07-28 2004-09-22 松下電器産業株式会社 デジタル地図の位置情報伝達方法とそれを実施する装置
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
WO2001041757A1 (en) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
AU2930501A (en) 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001318350A (ja) 2000-05-11 2001-11-16 Lion Corp コンタクトレンズ用溶液
JP4748289B2 (ja) 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
JP4564920B2 (ja) 2003-04-18 2010-10-20 株式会社最先端医学研究所 眼に適用する疾患治療剤
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
EP2052720A3 (en) 2003-11-20 2009-05-06 Othera Holding, Inc. Use of at least one hydroxylamine compound for the treatment of eye disease
JP2005187407A (ja) 2003-12-25 2005-07-14 Lion Corp アレルギー眼疾患用眼科組成物
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
PL380611A1 (pl) 2004-02-17 2007-02-19 President And Fellows Of Harvard College Postępowanie z zaburzeniami oftalmologicznymi, włącznie ze zwyrodnieniem plamki
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
WO2006049968A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
US20100160304A1 (en) 2005-01-19 2010-06-24 Dainippon Sumitomo Pharma Co., Ltd Aromatic sulfone compound as aldosterone receptor modulator
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN1830964B (zh) 2005-03-11 2011-06-15 中国科学院上海药物研究所 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途
US20060257488A1 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
US7973025B2 (en) * 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
US8435965B2 (en) 2005-12-27 2013-05-07 Lion Corporation Composition for soft contact lens and adsorption suppressing method
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
EP2012789B1 (en) 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
CA2658793A1 (en) 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
EP2069337A1 (en) 2006-08-14 2009-06-17 Schering Corporation Salts of 5 - ( l ( s ) -amino - 2 - hydroxyethyl ) -n- ý ( 2, 4 -difluorophenyl) -methyl¨- 2 - ý 8 -methoxy - 2 - (trifluoromethyl) - 5 - quinoline¨- 4 - oxazolecarboxamide
RU2434630C2 (ru) 2006-08-31 2011-11-27 Юранд, Инк. Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств
WO2008052086A1 (en) 2006-10-24 2008-05-02 Wyeth Benzodioxane derivatives and uses thereof
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
US8490764B2 (en) 2007-05-30 2013-07-23 Margaret Simester Portable storage and changing station
US20090118503A1 (en) 2007-06-20 2009-05-07 Kevin Sprott Faah inhibitors
RU2541430C2 (ru) 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
NZ617701A (en) 2008-02-11 2015-06-26 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction
CN102177157A (zh) 2008-08-12 2011-09-07 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并*唑类、苯并噻唑类和相关的类似物
BRPI0919920A2 (pt) * 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
EP2358660A2 (en) 2008-11-11 2011-08-24 Novartis AG Salts of fingolimod
JP2012520880A (ja) 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
MX2011013061A (es) 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas de fluticasona y metodos de uso.
WO2010148351A1 (en) 2009-06-18 2010-12-23 Cylene Pharmaceuticals, Inc. Rhodanines and related heterocycles as kinase inhibitors
WO2011008202A1 (en) 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
JPWO2011078204A1 (ja) 2009-12-24 2013-05-09 浜理薬品工業株式会社 高脂血症の予防または治療剤、および抗疲労剤
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
WO2011116066A1 (en) * 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
JP2011203665A (ja) 2010-03-26 2011-10-13 Ophtecs Corp コンタクトレンズの白濁解消用製剤及び白濁解消方法
SG10201506870PA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Salts of lorcaserin with optically active acids
EP2632441A4 (en) 2010-10-29 2015-04-01 Relmada Therapeutics Inc COMPOSITIONS OF (-) - 17- (CYCLOBUTYLMETHYL-) MORPHINAN-3,14-DIOL
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
WO2012100142A2 (en) 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
EP2670439B1 (en) 2011-01-31 2019-03-13 PVAC Medical Technologies Ltd. Active principle for mitigating undesired medical conditions
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP2766032A4 (en) 2011-10-13 2015-04-29 Thomas Gadek TOPICAL FORMULATIONS OF PEPTIDES CHÉMÉRINE C15 FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
WO2015187942A1 (en) 2014-06-04 2015-12-10 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US9817701B2 (en) 2011-12-12 2017-11-14 International Business Machines Corporation Threshold computing in a distributed computing system
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
JP6545618B2 (ja) 2012-08-01 2019-07-17 ルイス アンド クラーク ファーマスーティカルズ，インコーポレイテッドＬｅｗｉｓ ａｎｄ Ｃｌａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ａ２ａアゴニストとしてのｎ−アルキル２−（二置換）アルキニルアデノシン−５’−ウロンアミド
EA034963B1 (ru) 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
TWI624262B (zh) 2013-01-23 2018-05-21 桑紐爾製藥公司 醫藥配方
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
MX2015009444A (es) * 2013-01-25 2016-04-15 Aldeyra Therapeutics Inc Trampas novedosas en el tratamiento de la degeneracion macular.
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9713330B1 (en) * 2013-03-15 2017-07-25 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
US10736842B2 (en) 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
NO2721710T3 (es) 2014-08-21 2018-03-31
IL285760B2 (en) * 2014-09-02 2025-03-01 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
WO2016085939A2 (en) 2014-11-24 2016-06-02 Case Western Reserve University Compounds and methods of treating ocular disorders
US9953187B2 (en) 2014-11-25 2018-04-24 Honeywell International Inc. System and method of contextual adjustment of video fidelity to protect privacy
TWI876835B (zh) 2015-04-15 2025-03-11 英屬開曼群島商百濟神州有限公司 B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途
WO2017035082A1 (en) * 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Aldehyde conjugates and uses thereof
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
WO2017147617A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP3463277A4 (en) 2016-06-06 2020-01-01 GDD Therapeutics, LLC FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS THEREFOR AND USES THEREOF
CA3032521A1 (en) * 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
WO2018039197A1 (en) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
MX2019003623A (es) 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
WO2018067860A1 (en) 2016-10-05 2018-04-12 Mitobridge, Inc. Crystalline and salt forms of ppar agonist compounds
CN115089547A (zh) 2016-10-12 2022-09-23 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition
ES2968462T3 (es) * 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Sal polimórfica de 6-cloro-3-amino-2(2-hidroxiprolil) quinolina y usos de la misma
US10664688B2 (en) 2017-09-20 2020-05-26 Google Llc Systems and methods of detecting and responding to a visitor to a smart home environment
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
CA3078295C (en) 2017-12-14 2023-06-13 Lutron Technology Company Llc Privacy mode for a wireless audio device
WO2020018498A1 (en) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US10915995B2 (en) 2018-09-24 2021-02-09 Movidius Ltd. Methods and apparatus to generate masked images based on selective privacy and/or location tracking
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
JP2022503994A (ja) 2018-10-02 2022-01-12 アルデイラ セラピューティクス， インコーポレイテッド コンタクトレンズ溶液およびキット
EP3890732A4 (en) 2018-12-05 2022-08-24 Aldeyra Therapeutics, Inc. INJECTABLE FORMULATIONS
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP7682512B2 (ja) 2019-09-13 2025-05-26 アルデイラ セラピューティクス， インコーポレイテッド メトトレキサートの眼科用製剤
US20230131929A1 (en) 2020-03-24 2023-04-27 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
JP2023522000A (ja) * 2020-04-13 2023-05-26 アルデイラ セラピューティクス， インコーポレイテッド 肺、肝臓、および腎臓の疾患、障害、または状態を処置するためのキノリン化合物
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2021248031A1 (en) 2020-06-04 2021-12-09 Aldeyra Therapeutics, Inc. Dry eye disease biomarkers and their use for treatment
CN112541870A (zh) 2020-12-07 2021-03-23 北京大米科技有限公司 一种视频处理的方法、装置、可读存储介质和电子设备
US20220211691A1 (en) 2021-01-07 2022-07-07 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
WO2022150580A1 (en) 2021-01-07 2022-07-14 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
CN112800947A (zh) 2021-01-27 2021-05-14 上海电气集团股份有限公司 视频监控方法、系统、电子设备及存储介质
BR112023025660A2 (pt) 2021-07-02 2024-02-27 Aldeyra Therapeutics Inc Compostos de captação de aldeído heterocíclicos e usos dos mesmos
US20250228840A1 (en) 2022-03-29 2025-07-17 Aldeyra Therapeutics, Inc. Methods of treating sjögren-larssen syndrome

Also Published As

Publication number Publication date
BR112018003250A2 (pt) 2018-09-25
JP2021167358A (ja) 2021-10-21
KR20180073554A (ko) 2018-07-02
EP4400106A1 (en) 2024-07-17
EP3337486A1 (en) 2018-06-27
CN118724806A (zh) 2024-10-01
CO2018002822A2 (es) 2018-05-31
US11845722B2 (en) 2023-12-19
WO2017035077A1 (en) 2017-03-02
US11459300B2 (en) 2022-10-04
CN108135907A (zh) 2018-06-08
US20240132451A1 (en) 2024-04-25
ZA201801678B (en) 2019-01-30
EP3337486B1 (en) 2024-04-03
JP6947406B2 (ja) 2021-10-13
US20210347735A1 (en) 2021-11-11
US10550085B2 (en) 2020-02-04
JP2018523700A (ja) 2018-08-23
EP3337486A4 (en) 2019-03-06
KR102664994B1 (ko) 2024-05-13
HK1256980A1 (en) 2019-10-11
AU2016311158A1 (en) 2018-04-05
IL257611A (en) 2018-04-30
MX2018002155A (es) 2018-06-08
US20200199075A1 (en) 2020-06-25
US12240816B2 (en) 2025-03-04
CA2996183A1 (en) 2017-03-02
US20180354905A1 (en) 2018-12-13
US11046650B2 (en) 2021-06-29
ES2989113T3 (es) 2024-11-25
US20230174491A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CL2018000463A1 (es) Compuestos deuterados y usos de los mismos
CO2019001625A2 (es) Compuestos de captura de aldehído y usos de los mismos
CO2018002841A2 (es) Conjugados de aldehído y usos de los mismos
MX2015009383A (es) Enfermedades relacionadas con aldehido toxico y tratamiento.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CO2018013585A2 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para uso en el tratamiento de transtornos neurodegenerativos.
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2016011034A (es) Compuestos de amida para el tratamiento de trastornos mediados por complemento.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2017005283A (es) Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
UY35393A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
CL2019000027A1 (es) Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes.
CL2017001773A1 (es) Análogos de calcitonina para tratar enfermedades y trastornos.
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES
CL2018003013A1 (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.